Χώρα: Ιρλανδία
Γλώσσα: Αγγλικά
Πηγή: HPRA (Health Products Regulatory Authority)
Ciprofloxacin lactate
Claris Lifesciences (UK) Limited
J01MA; J01MA02
Ciprofloxacin lactate
2 milligram(s)/millilitre
Solution for infusion
Product subject to prescription which may not be renewed (A)
Fluoroquinolones; ciprofloxacin
Not marketed
2008-06-20
PACKAGE LEAFLET: INFORMATION FOR THE USER CIPROFLOXACIN 2 MG/ML SOLUTION FOR INFUSION CIPROFLOXACIN READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. IN THIS LEAFLET: 1. What Ciprofloxacin Infusion is and what it is used for 2. What you need to know before you are given Ciprofloxacin Infusion 3. How to take Ciprofloxacin Infusion 4. Possible side effects 5. How to store Ciprofloxacin Infusion 6. Contents of the pack and other information 1. WHAT CIPROFLOXACIN INFUSION IS AND WHAT IT IS USED FOR Ciprofloxacin Infusion contains the active substance ciprofloxacin. Ciprofloxacin is an antibiotic belonging to the fluoroquinolone family. Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria. Adults Ciprofloxacin Infusion is used in adults to treat the following bacterial infections: respiratory tract infections long lasting or recurring ear or sinus infections urinary tract infections genital tract infections in men and women gastro-intestinal tract infections and intra-abdominal infections skin and soft tissue infections bone and joint infections anthrax inhalation exposure Ciprofloxacin may be used in the management of patients with low white blood cell counts (neutropenia) who have a fever that is suspected to be due to a bacterial infection. If you have a severe infection or one that is caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to Ciprofloxacin infusion. Children and Adolescent Διαβάστε το πλήρες έγγραφο
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ciprofloxacin 2mg/ml, Solution for Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each presentation of Ciprofloxacin 2mg/ml infusion contains the following: CIPROFLOXACIN 100 MG/50 ML, SOLUTION FOR INFUSION 1 ml of Solution for Infusion contains 2mg Ciprofloxacin as 2.544mg Ciprofloxacin lactate. Each 50 ml vial or Non-PVC bag contains 100 mg Ciprofloxacin (as Ciprofloxacin Lactate). Excipient: Each 50ml contains 7.7 mmol (177 mg) Sodium. CIPROFLOXACIN 200 MG/100 ML, SOLUTION FOR INFUSION 1 ml of Solution for Infusion contains 2mg Ciprofloxacin as 2.544mg Ciprofloxacin lactate Each 100 ml vial or Non-PVC bag contains 200 mg Ciprofloxacin. (as Ciprofloxacin Lactate). Excipient: Each 100ml contains 15.4 mmol (354 mg) Sodium. CIPROFLOXACIN 400 MG/200 ML, SOLUTION FOR INFUSION 1 ml of Solution for Infusion contains 2mg Ciprofloxacin as 2.544mg Ciprofloxacin lactate. Each 200 ml bottle or Non-PVC bag contains 400 mg Ciprofloxacin. (as Ciprofloxacin Lactate). Excipient: Each 200 ml contains 30.8 mmol (708 mg) Sodium. For a full list of excipients see section 6.1 3 PHARMACEUTICAL FORM Solution for infusion Clear, colourless to slightly yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ciprofloxacin solution for infusion is indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy. Consideration should be given to official guidance on the appropriate use of antibacterial agents. _Adults_ • Lower respiratory tract infections due to Gram-negative bacteria - exacerbations of chronic obstructive pulmonary disease - broncho-pulmonary infections in cystic fibrosis or in bronchiectasis - pneumonia H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Διαβάστε το πλήρες έγγραφο